Based on these findings, we propose that CD24/SIGLEC10 could serve as a novel target for cancer immunotherapy, potentially enabling the investigation of monoclonal anti‐CD24 antibodies as a new treatment for NB.67 This evidence concerns the gene CD24 and cancer.